Life Science Investor Mandates
(Feb. 14 - Feb. 20
)
|
|
|
|
|
Seeks to Invest $5-10M in Promising Biotech and Medtech Companies in USA, China, and Europe
|
|
Seeks to Invest in Small Molecule Therapeutics & IND-Ready Biologics in High Unmet Need Areas, as well as Medtech & Diagnostics Companies
|
|
Seeks to Partner with Therapeutic Assets in CNS and Immunology Indications, Assisting Clinical Development
|
|
Invests in Therapeutics & Digital Health Companies, with Interests in Digital Therapeutics, Precision Medicine, Data Enabling Technologies, etc.
|
|
|
By Lucy Parkinson, VP of Investor Research, LSN
 With just days to go until RESI Partnering opens, investors have been flocking to RESI Europe from around the world. You can see below for who's going to be there - from major pharma firms to family offices to regional and global VCs, there's an abundance of capital on the table. If you'd like to be in the RESI Partnering action when we launch on Monday, you can register now.
Confirmed RESI Vienna Investors
As of Feb. 20th
|
|
Fundraising & Valuation Boot Camp in Europe
February 27th - Basel Area
WHEN: 27 February, 09:00 am - 12:30 pm
WHERE: Switzerland Innovation Park - Basel Area
February 28th - Heidelberg
WHEN:
28 February, 09:00 am - 12:30 pm
WHERE:
Conference Center Technology Park, Heidelberg
|
|
 |
|
An interview with
Chuck Stetson, CEO, Stetson Family Office
- By
Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
|
|
The Stetson Family Office has been active in driving global initiatives between two key investor groups: family offices that have desire and dollars to impact global health, and regional angel groups who have the ability to vet and recommend compelling early stage life science technologies. These alliances have the power to accelerate early stage investment across the silos of drugs, devices, diagnostics and digital health. There is a multitude of global early stage life science startups that are in need of early stage funding partners who can provide the capital to develop the next generation healthcare products. These next generation products will have a great impact on virtually everybody on the planet.
Dennis:
Chuck, what exactly is the Global Family Office BioForum (GFOB)? How many Family Offices participate and how many cities throughout the world?
Chuck:I created and launched the entity Global BioForum because like my own family office, I discovered there were other family offices that are genuinely interested in philanthropy and social impact investing in healthcare, but finding and vetting the technology assets proved to be a challenge for them because of limited staff. To meet the challenge I created a strategy to match up regional angel networks with up to 40 members vetting each deal with regional family offices within the early stage life science arena...
|
 |
|
By Claire Jeong, Senior Research Analyst, LSN
 Life Science Nation is busily preparing for our inaugural RESI Europe event at Vienna, Austria on Monday, March 25th, and we are excited to announce our Big Pharma panel! There is no doubt that major pharmaceuticals are continuing to explore creative approaches in partnering with early-stage companies, extending beyond the scope of traditional therapeutics. Companies fully understand the value of developing strategic partnerships with big pharma, but it can be a challenge to get in front of the right team.
As companies want to better understand the implications of partnering with big pharma, this panel has been one of our most popular topics since the inception of RESI - here is our lineup of panelists:
- Florence Dal Degan, R&D Innovation Sourcing Director, Novo Nordisk
- Olaf Koenig, Director, International Business Development, Amgen
- Natalia Novac, Director, Emerging Technology & Innovation, Corporate Business Development, Eli Lilly & Co
- Chris Church, Manager, Partnering and Strategy, AstraZeneca
|
|
|
|
|
|
|
Created & Produced by
|
 |
|
|
|
